Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Top Ten Unpartnered Drugs: It's Tough To Make The Grade In CVD/Metabolics

This article was originally published in The Pink Sheet Daily

Executive Summary

Early-stage talent parade will be held at Windhover's Therapeutic Area Partnerships conference next week.

You may also be interested in...



Top Partnering Opportunities In Cardiovascular Disease/Metabolics

Market Snapshot: Obesity Space Is ‘Not For The Faint of Heart’

Several anti-obesity treatments are in the home stretch of late-stage development, promising to rev up a stagnant market and satisfy pent-up demand. But there's an elephant in the weight loss room - nobody seems to know who will pick up the tab for new drugs

Tekturna Will Track Diovan’s Steady Growth To Blockbuster Status - Novartis

Novartis is hoping sales of its new blood pressure drug Tekturna will climb steadily as morbidity and mortality data amass, eventually leading it to blockbuster status on the same trajectory as top-selling Diovan

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel